Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Revenue from product sales	$ 337	$ 270
Collaboration revenue	18	222
Total revenue	355	492
Cost of product sales	696	426
Cost of collaboration revenue	1	296
Total cost of revenue	697	722
Gross loss	(342)	(230)
Research and development expenses	8,400	9,968
Selling, general and administrative expenses	9,773	11,285
Intangible asset impairment expense	3,905	0
Restructuring costs	335	0
Operating loss	(26,479)	(37,407)
Other income (expense):
Warrant revaluation income	11,884	2,929
Derivative revaluation expense	(462)	0
Interest expense	(228)	0
Other income (expense), net	(7)	25
Loss before income taxes	(15,292)	(34,453)
Income tax benefit	0	0
Net loss	$ (15,292)	$ (34,453)
Per Share Information:
Net loss per share, basic (in dollars per share)	$ (0.35)	$ (0.82)
Net loss per share, diluted (in dollars per share)	$ (0.39)	$ (0.85)
Weighted average number of common shares outstanding
Weighted average number of common shares outstanding - basic (in shares)	43,924,404	42,178,397
Weighted average number of common shares outstanding - diluted (in shares)	43,942,421	42,351,346
Affiliated Entity
Research and development expenses	$ 3,724	$ 15,924